TESARO, Roche to evaluate triplet therapy for ovarian cancer

Drug Discovery |  News | 0 Comment | 06 Jun, 2018

Singapore-  TESARO, an oncology-focused biopharmaceutical company, announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate ...Read more

USFDA grants Priority Review to Astellas's NDA for Gilteritinib

Drug Discovery |  News | 0 Comment | 05 Jun, 2018

Japan’s Astellas Pharma recently announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug Application (NDA) for gilteritin...Read more

Versartis, Aravive enter into merger agreement

Drug Discovery |  News | 0 Comment | 04 Jun, 2018

Singapore- Versartis and Aravive Biologics jointly announced that they have entered into a definitive agreement under which Aravive will merge with a wholly owned subsidiary of Versartis in...Read more

Blueprint inks deal on oncology therapies with CStone

Drug Discovery |  News | 0 Comment | 04 Jun, 2018

Singapore- Blueprint Medicines and CStone Pharmaceuticals, a privately-held biopharmaceutical company announce an exclusive collaboration and license agreement for the development and ...Read more

Lilly and Incyte's drug gets FDA approval

Drug Discovery |  News | 0 Comment | 04 Jun, 2018

Singapore- Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT (baricitinib), a once-daily or...Read more

Amgen’s Biosimilar fails to get FDA approval

Drug Discovery |  News | 0 Comment | 04 Jun, 2018

Singapore- Amgen, in a two-sentence announcement, said it received a complete response letter for the biosimilar of Roche’s cancer med Herceptin it developed with Allergan. It marks t...Read more

EC approves Roche’s Perjeta for HER2-positive early breast cancer

Drug Discovery |  News | 0 Comment | 03 Jun, 2018

Global drug giant, Roche recently announced that the European Commission has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based re...Read more

LUYE pharma Joins US Firm to Develop Immuno-oncology Treatments

Drug Discovery |  News | 0 Comment | 29 May, 2018

LUYE PHARMA announced that the Group entered into a collaboration and license agreement with Elpis Biopharm, a Boston-region Biotechnology company, to discover and develop dual target based...Read more

FDA approves BioMarin’s metabolic disorder treatment

Drug Discovery |  News | 0 Comment | 25 May, 2018

Singapore- U.S. regulators approved BioMarin Pharmaceutical Inc’s Palynziq for adults with phenylketonuria, a rare metabolic disorder. Phenylketonuria, or PKU, is a rare genetic dise...Read more

Eisai, Merck provide Update on sNDA for Lenvatinib

Drug Discovery |  News | 0 Comment | 25 May, 2018

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the suppleme...Read more

Celgene, Evotec team up on cancer treatments

Drug Discovery |  News | 0 Comment | 22 May, 2018

Singapore- Celgene and German biotech Evotec AG have inked a long-term strategic drug discovery and development partnership to identify new cancer therapies, 18 months after the t...Read more

AstraZeneca submits sNDA for Forxiga in Japan

Drug Discovery |  News | 0 Comment | 22 May, 2018

Global drug giant, AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (...Read more

Minerva’s drug shows treatment effect in schizophrenia patients

Drug Discovery |  News | 0 Comment | 18 May, 2018

 Singapore- Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), announced that Th...Read more

Cabometyx gets approval in Europe for first-line kidney cancer

Drug Discovery |  News | 0 Comment | 18 May, 2018

 Singapore- The European Commission (EC) has approved commercialization partner Ipsen's marketing application for CABOMETYX (cabozantinib) 20, 40, 60 mg for the first-line treatment of...Read more

Regeneron, Sanofi's drug shows positive effect in lung cancer study

Drug Discovery |  News | 0 Comment | 18 May, 2018

 Singapore- Regeneron Pharmaceuticals and development partner Sanofi announce positive preliminary data from a Phase 1 clinical trial assessing cemiplimab in advanced non-small ce...Read more

Dicerna’s hyperoxaluria treatment gets orphan status from FDA

Drug Discovery |  News | 0 Comment | 18 May, 2018

 Singapore- Dicerna Pharmaceutical’s drug recently received an orphan drug status designation for its treatment for primary hyperoxaluria. The FDA granted the status t...Read more

FDA approves first non-opioid treatment for opioid withdrawal

Drug Discovery |  News | 0 Comment | 17 May, 2018

Singapore- The U.S. Food and Drug Administration approved privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrup...Read more

Daré to merge with Pear Tree Pharma

Drug Discovery |  News | 0 Comment | 08 May, 2018

Singapore– Daré Bioscience, a clinical-stage women’s biopharmaceutical company has agreed to merge with Pear Tree Pharmaceuticals, a development-stage wome...Read more